Control
Recent:Brown.
Sep 30 2023 |
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(23)00147-9 | Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial |
| 6% higher mortality (p=0.71) and 10% lower progression (p=0.54). RCT 461 hospitalized patients with COVID-19-associated respiratory failure showing no significant difference in outcomes with aviptadil treatment. | ||
Aug 29 2022 |
et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005660 | The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial |
| 35% lower mortality (p=0.04) and 20% lower progression (p=0.27). RCT 196 patients with critical COVID-19 respiratory failure showing improved survival but no significant difference in the primary endpoint of "alive and free of respiratory failure at day 60" with IV aviptadil. | ||
Mar 31 2022 |
et al., NCT04488081 | I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI® (aviptadil) When Given by Mouth Inhalation in Critically Ill Patients with COVID-19 |
| 79% worse recovery (p=0.02). RCT 118 patients showing significantly worse recovery with aviptadil treatment. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.